bg content top team

Meet our Experienced
and Multidisciplined Team


Jason Laufer, Chief Executive Officer
Jason is a seasoned veteran in the biopharmaceutical field, with early experience in clinical and regulatory affairs at Pfizer (PFE), and at a senior level, as Managing Director of CELLGRO®/Mediatech; acquired by Corning (GLW). Mr. Laufer, operating via the VIDA Group, has provided management consulting services to a range of European, US, and Israeli Pharma companies, and was appointed CEO of ELUTEX, a developer of drug-eluting stents. Prior to assuming the helm at RDD, Mr. Laufer managed Global Business Development and Licensing for URL Pharma, a specialty pharma company with a portfolio in gout (Colcrys), lipid regulation (Fibricor), antibiotics (Bactrim), malaria (Qualaquin) as well as a generic drug portfolio of 250 ANDAs. URL Pharma was acquired by Takeda Pharmaceuticals in 2012 for $800 million plus potential follow-on payments.

Nir Barak M.D., Chief Medical Officer and Founder
Dr. Barak’s career has focused on the integration of clinical medicine, basic research, and pharmaceutical development. He served as an attending physician in the department of internal medicine at Beilinson Hospital for 10 years.

Dr. Barak began engaging in drug development driven by feedback received from patients regarding shortcomings in available treatment options. Nir served as CSO and Founder of Obecure Ltd. — a company focused on re-purposing Betahistine as an anti-obesity agent. In 2008 after learning from patients of the dearth of treatment options for ano-rectal diseases, he founded RDD Pharma. Under Nir’s leadership, RDD has attracted  significant investment from OrbiMed Advisors. — a multinational private equity fund.

Dr. Barak earned his MD from the Sackler School of Medicine, Tel-Aviv University, and is Board Certified in Internal Medicine and Clinical Nutrition.

Howard Rice, RPh, BPharm, Vice President — Pharmaceuticals
Howard brings 30+ years of pharmaceutical formulation and development experience to RDD. Mr. Rice serves as a Director at Tilary Ltd, the Israel agent for American Biotech Labs (USA) and is the Israel delegate to the Federation International Pharmaceutique (FIP) – an NGO within the World Health Organization (WHO). He served as Vice President of the FIP for 8 years, and he is the former Chairman of the Pharmaceutical Association of Israel.

Mr. Rice earned a B.Pharm from the School of Pharmacy, University of London.

Robert Niecestro, Ph.D. — Regulatory Advisor
Robert is the managing director of Accelapharm. He serves as the Head of Regulatory Affairs and Vice President of Axsome Therapeutics. Dr. Niecestro also serves as the Executive Vice President of Clinical & Regulatory at TG Therapeutics, Inc. He was a regulatory consultant to Stemline Therapeutics from 2006 until December 2012.  Dr. Niecestro served as the VP Clinical & Regulatory Affairs at Keryx Biopharmaceuticals, Inc., where he negotiated six SPA agreements and filed the NDA for ferric citrate. He has held executive and senior management roles at Andrx Laboratories, Eisai Inc. and Organon Inc. He has been involved in the filing of over 45 Investigational New Drug (IND) applications. He has over 60 peer-reviewed publications and holds three patents.

Ariel Kamsler, Ph.D. — Director, Clinical Operations
Ariel joined RDD in 2014. He was previously with CTS Pharmaceuticals where he led all aspects of generic drug development. Prior to CTS, Dr. Kamsler was at Teva Pharmaceuticals – initially with the Advanced Drug Delivery group, and later with Teva Innnovative Ventures where he led due-diligence, project management and evaluation of new drugs.

Dr. Kamsler earned his PhD in Neurobiology at the Weizmann Institute and was a post-doc at MIT in the laboratory of Nobel Laureate Susumu Tonegawa.


Our team is balanced by responsible stewardship and innovative drive.


    •    OrbiMed Advisors
    •    Ofakim Hi-Tech Ventures
    •    CFH – Corporate Finance
          Holding GmbH

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2017, RDD Pharma, Ltd. All rights reserved.


Go to top